Technical Analysis for ORIC - Oric Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
D | 8.55 | -2.84% | -0.25 |
ORIC closed down 2.84 percent on Friday, May 24, 2024, on 1.25 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Jun 12
*** please verify all earnings dates ***ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Bollinger Band Squeeze | Range Contraction | 0.00% | |
Stochastic Reached Oversold | Weakness | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Fell Below 20 DMA | Bearish | -2.84% | |
Bollinger Band Squeeze | Range Contraction | -2.84% | |
BB Squeeze Started | Range Contraction | -2.84% | |
Outside Day | Range Expansion | -2.84% | |
Crossed Above 20 DMA | Bullish | -6.76% |
Alert | Time |
---|---|
Possible Inside Day | 3 days ago |
Up 1% | 3 days ago |
60 Minute Opening Range Breakout | 3 days ago |
Down 3% | 4 days ago |
Fell Below Lower Bollinger Band | 4 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 06/12/2024
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Treatment Treatment Of Cancer Oncology Chemotherapy Antineoplastic Drugs Occupational Safety And Health Precision Medicine Specialty Drugs Cancer Therapeutics Cd73
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 16.63 |
52 Week Low | 4.91 |
Average Volume | 509,860 |
200-Day Moving Average | 9.31 |
50-Day Moving Average | 10.45 |
20-Day Moving Average | 9.14 |
10-Day Moving Average | 9.00 |
Average True Range | 0.60 |
RSI (14) | 37.89 |
ADX | 20.2 |
+DI | 13.64 |
-DI | 23.87 |
Chandelier Exit (Long, 3 ATRs) | 8.34 |
Chandelier Exit (Short, 3 ATRs) | 9.43 |
Upper Bollinger Bands | 9.87 |
Lower Bollinger Band | 8.41 |
Percent B (%b) | 0.1 |
BandWidth | 16.00 |
MACD Line | -0.34 |
MACD Signal Line | -0.39 |
MACD Histogram | 0.0481 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 9.17 | ||||
Resistance 3 (R3) | 9.22 | 9.06 | 9.06 | ||
Resistance 2 (R2) | 9.06 | 8.91 | 9.04 | 9.03 | |
Resistance 1 (R1) | 8.81 | 8.81 | 8.73 | 8.76 | 8.99 |
Pivot Point | 8.65 | 8.65 | 8.62 | 8.63 | 8.65 |
Support 1 (S1) | 8.40 | 8.50 | 8.32 | 8.35 | 8.11 |
Support 2 (S2) | 8.24 | 8.40 | 8.22 | 8.07 | |
Support 3 (S3) | 7.99 | 8.24 | 8.04 | ||
Support 4 (S4) | 7.94 |